Invertebrate animal models of diseases as screening tools in drug discovery.
about
Fishing for Nature's Hits: Establishment of the Zebrafish as a Model for Screening Antidiabetic Natural ProductsC. elegans in high-throughput drug discoveryThe Parallel Worm Tracker: a platform for measuring average speed and drug-induced paralysis in nematodesDevelopment and validation of an automated high-throughput system for zebrafish in vivo screeningsA High-Throughput Small Molecule Screen for C. elegans Linker Cell Death InhibitorsSystematic NMR analysis of stable isotope labeled metabolite mixtures in plant and animal systems: coarse grained views of metabolic pathwaysMicrofluidic system for on-chip high-throughput whole-animal sorting and screening at subcellular resolution.Preclinical assessment of CNS drug action using eye movements in mice.In vivo analysis of compound activity and mechanism of action using epistasis in Drosophila.Control of feeding behavior in C. elegans by human G protein-coupled receptors permits screening for agonist-expressing bacteria.High-throughput screening and small animal models, where are we?In vivo imaging of Caenorhabditis elegans glycansHTS and hit finding in academia--from chemical genomics to drug discovery.Characterization of low molecular weight chemical fractions of dry bean (Phaseolus vulgaris) for bioactivity using Caenorhabditis elegans longevity and metabolite fingerprinting.Using C. elegans for antimicrobial drug discovery.A novel zebrafish human tumor xenograft model validated for anti-cancer drug screening.A Cys-loop mutation in the Caenorhabditis elegans nicotinic receptor subunit UNC-63 impairs but does not abolish channel functionChemical screen reveals small molecules suppressing fragile X premutation rCGG repeat-mediated neurodegeneration in Drosophila.Nanodiamond for biolabelling and toxicity evaluation in the zebrafish embryo in vivo.Development of a vestibular schwannoma xenograft zebrafish model for in vivo antitumor drug screening.Dietary Plant Lectins Appear to Be Transported from the Gut to Gain Access to and Alter Dopaminergic Neurons of Caenorhabditis elegans, a Potential Etiology of Parkinson's Disease.The necessity for in vivo functional analysis in human medical genetics.Accelerating the development of novel molecular imaging probes: a role for high-throughput screeningThe Simple Chordate Ciona intestinalis Has a Reduced Complement of Genes Associated with Fanconi Anemia.Pharmacological approaches to restore mitochondrial function.Variation of lifespan in multiple strains, and effects of dietary restriction and BmFoxO on lifespan in silkworm, Bombyx mori.Chemistry and the worm: Caenorhabditis elegans as a platform for integrating chemical and biological research.Wormometry-on-a-chip: Innovative technologies for in situ analysis of small multicellular organisms.Drosophila as a model to study the genetic mechanisms of obesity-associated heart dysfunction.Novel models for assessing blood-brain barrier drug permeation.Animal models for drug discovery in dystonia.Effect of pulse direct current signals on electrotactic movement of nematodes Caenorhabditis elegans and Caenorhabditis briggsae.Therapy with antitumor lipids: worming the way.Using Caenorhabditis elegans as a Model for Obesity Pharmacology Development.Characterization of midazolam metabolism in locusts: the role of a CYP3A4-like enzyme in the formation of 1'-OH and 4-OH midazolam.Electrotaxis of Caenorhabditis elegans in a microfluidic environment.Why mammalian wound-healing researchers may wish to turn to Drosophila as a model.
P2860
Q26774936-9E535304-28B9-4A6C-A151-346E4BBBB986Q27027125-4152CBD9-27C9-4C71-BD04-21B422475CD7Q27301328-2BCDE356-C7B5-47FF-9DB7-32503A73E401Q27303272-5814CFF0-AF18-4B75-B49A-84E8CB3B0C85Q27320254-BF5E591A-4D22-4FB2-A662-86480C10CCCEQ28474093-BC495EDC-6861-40A5-8EC6-6133B3BCE819Q30479992-C9155511-09D6-4402-AE14-7786B8845077Q30503853-D43B6B8F-2730-4D54-89A9-6AD3C3D777FCQ31043762-E79EE2C4-0474-4295-8735-83C1B1BE81E7Q33371683-7DDEC134-2228-460A-B5A6-8F0282E6FAD6Q33566144-1323CC63-26DA-455D-A9EB-826B6CBAAD6CQ33595565-16E41641-C771-49C7-8968-5F13C5AE313FQ33621193-37A7791A-F9A9-46FA-8E50-D4D1B7A51362Q33908106-D438BE1D-4065-460F-A53A-E21560B5FC3DQ33936475-AD75AD32-4C94-4003-8345-19DA50F878CDQ34262700-80DD1470-0081-43BE-9933-6576ABF2B7E5Q34509316-0BDDB2D9-B0F4-4FE6-9EAE-E21F5555773EQ35860358-99093CE6-9BB4-4CF4-8488-91282DE03654Q35993955-A38FD821-01A7-44E6-994A-DA3AC7AE28F4Q36034475-8F64A14A-0D5C-4C71-904A-84A2B385ED44Q36657924-FE8B3EF7-3E89-4478-8097-0CAC2D6D3BD3Q36683908-FE957EAF-C835-4DBF-B04D-57A708EB990CQ36957122-8E15347D-5BD3-4AF0-9B7E-75E2824B61E5Q36982306-0D67CCFF-978F-4946-A48E-4894ACAA7D4DQ37497833-1F958384-FB4F-4CFF-B732-9D2C9687EB52Q37702507-D4A4C2B4-60A7-4862-BF0B-3377AD088156Q37866234-AF8A0F76-FCFA-4304-9017-8EDF19EFBE33Q37872688-02A97797-15B6-412C-917B-FA03C611AB60Q37981226-1C5E3E41-055B-498E-861C-C287A69120D0Q37999058-039B56B7-4DEE-48AF-AC2B-E7355BDE1B1DQ38088284-BDDBC005-9BF3-40D9-864C-0095795ADC11Q40239186-07DA1916-4B53-4ADD-9819-3EC1EA2A7E24Q43207114-B0396E4E-A293-49C1-9E94-534BC91B3B05Q47121505-37EF5EBF-1F0E-4F7D-A2FB-DF70F08ADE73Q47671297-6BEAAB5A-A92C-4182-94F2-6E4F4BDEADC3Q51560971-577FC743-BBC2-4E20-8376-A48A3F0F5F26Q52774513-6BF2E55C-D9FC-4881-8FBF-4BE07B1D1A51
P2860
Invertebrate animal models of diseases as screening tools in drug discovery.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Invertebrate animal models of diseases as screening tools in drug discovery.
@ast
Invertebrate animal models of diseases as screening tools in drug discovery.
@en
type
label
Invertebrate animal models of diseases as screening tools in drug discovery.
@ast
Invertebrate animal models of diseases as screening tools in drug discovery.
@en
prefLabel
Invertebrate animal models of diseases as screening tools in drug discovery.
@ast
Invertebrate animal models of diseases as screening tools in drug discovery.
@en
P356
P1433
P1476
Invertebrate animal models of diseases as screening tools in drug discovery.
@en
P2093
Laurent Ségalat
P304
P356
10.1021/CB700009M
P577
2007-04-01T00:00:00Z